NEUROCRINE BIOSCIENCES INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this report:
| Exhibit | ||
|---|---|---|
| 3.1 | Description: | Certificate of Incorporation, as amended |
| Reference: | Incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on November 5, 2018 | |
| 3.2 | Description: | Bylaws, as amended |
| Reference: | Incorporated by reference to Exhibit 3.2 of the Company's Quarterly Report on Form 10-Q filed on October 30, 2024 | |
| 4.1 | Description: | Form of Common Stock Certificate |
| Reference: | Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No. 333-03172) | |
| 10.1+ | Description: | Form of Stock Option Grant Notice and Option Agreement for grants made on or after January 30, 2025 made under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan |
| 10.2+ | Description: | Neurocrine Biosciences, Inc. Executive Severance Plan effective February 7, 2025 |
| Reference: | Incorporated by reference to Exhibit 10.26 of the Company’s Annual Report on Form 10-K filed on February 10, 2025 | |
| 10.3+ | Description: | Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Kyle W. Gano, Ph.D. |
| Reference: | Incorporated by reference to Exhibit 10.31 of the Company’s Annual Report on Form 10-K filed on February 10, 2025 | |
| 10.4+ | Description: | Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Matthew C. Abernethy |
| Reference: | Incorporated by reference to Exhibit 10.32 of the Company’s Annual Report on Form 10-K filed on February 10, 2025 | |
| 10.5+ | Description: | Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Eric Benevich |
| Reference: | Incorporated by reference to Exhibit 10.33 of the Company’s Annual Report on Form 10-K filed on February 10, 2025 | |
| 10.6+ | Description: | Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Jude Onyia |
| Reference: | Incorporated by reference to Exhibit 10.34 of the Company’s Annual Report on Form 10-K filed on February 10, 2025 | |
| 10.7+ | Description: | Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Eiry W. Roberts |
| Reference: | Incorporated by reference to Exhibit 10.35 of the Company’s Annual Report on Form 10-K filed on February 10, 2025 | |
| 10.8* | Description: | Amended and Restated Exclusive License Agreement dated January 24, 2025 by and between Takeda Pharmaceutical Company Limited and the Company |
| 31.1 | Description: | Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934 |
| 31.2 | Description: | Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934 |
| 32** | Description: | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Description: | Inline XBRL Instance Document. – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Description: | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Description: | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Description: | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Description: | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | Description: | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Description: | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101) |
- Management contract or compensatory arrangement.
- Certain information in this exhibit has been omitted pursuant to Item 601 of Regulation S-K.
** These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Except as specifically noted above, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K have a Commission File Number of 000-22705.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.